AstraZeneca PLC (AZN)vsCibus Global LLC (CBUS)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
CBUS
Cibus Global LLC
$1.57
-0.95%
HEALTHCARE · Cap: $119.99M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1411586% more annual revenue ($61.37B vs $4.35M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CBUS
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+88.0%
Fair Value
$17.44
Current Price
$1.57
$15.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 8.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CBUS
CBUS has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CBUS
The primary concerns for CBUS are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.21 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while CBUS is a value play — different risk/reward profiles.
CBUS carries more volatility with a beta of 1.59 — expect wider price swings.
CBUS is growing revenue faster at 6.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 18/100), backed by strong 17.0% margins. CBUS offers better value entry with a 88.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cibus Global LLC
HEALTHCARE · BIOTECHNOLOGY · USA
Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?